# Ollin Bio

> Retina biotech developing OLN324, a VEGF/Ang2 bispecific for DME and wet AMD.

## Why it is interesting

Head-to-head beat Vabysmo in trials — a16z Bio+Health joined a $330M Series B (2026) co-led by ARCH and TCGX for global Phase III.

## Profile

- **Stage:** series-b
- **Status:** private
- **Industries:** biotech-life-sciences, healthtech
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series B (2026): $330M co-led by ARCH and TCGX; a16z Bio+Health participated (AllSci, press)
- Co-investors not in VCT directory: TCGX, Commodore Capital, RA Capital, CPP Investments

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz
- https://venturecapitaltracker.com/fund/arch-venture-partners

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/ollin-bio